530486 Sigma-Aldrichp38 MAP Kinase Inhibitor XX, FGA-19 - Calbiochem
A cell-permeable compound that targets p38 C-terminal "docking domain. Selectively inhibits MEF-2A phosphorylation by activated p38α (IC₅₀ = 6.31 µM)
More>> A cell-permeable compound that targets p38 C-terminal "docking domain. Selectively inhibits MEF-2A phosphorylation by activated p38α (IC₅₀ = 6.31 µM) Less<<Synonyms: N-(5-Chloro-2-methylphenyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, FGA 19
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
Empirical Formula |
---|
C₁₃H₉ClN₄O₃ |
Description | |
---|---|
Overview | This product has been discontinued. A cell-permeable, benzoxadiazole compound designed to target p38 c-terminal "docking domain" that mediates interactions with upstream regulators and downstream substrates outside p38 active center. Selectively inhibits MEF-2A phosphorylation by activated p38α (IC50 = 6.31 µM; [p38] = 1 nM, [MEF-2a] = 10 nM, [ATP] = 25 µM) with little or no potency against a panel of other kinases or the docking site interaction-independent MBP phosphorylation by p38. Shown to inhibit LPS-stimulated phosphorylation of p38, MK2, and Hsp27 in THP-1 cells (1 to 5 µM; 1 h drug preincubation), while reduced inhibition against JNK1 & Erk1/2 is only observed at a high concentration of 5 µM. Although SB203580 (Cat. Nos. 559389, 559395, and 559398) exhibits similar potency as FGA-19 in inhibiting LPS-induced TNFα secretion in THP-1 cultures in vitro, only FGA-19 (1 µg/5 µL/mouse), but not SB203580 (up to 5 µg/mouse), intrathecal injection results in lasting (>5 days) reduction of heat sensitivity of paws received carrageenan injection among either wild-type or LysM-GRK2+/- mice in vivo. |
Catalogue Number | 530486 |
Brand Family | Calbiochem® |
Synonyms | N-(5-Chloro-2-methylphenyl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, FGA 19 |
References | |
---|---|
References | Willemen, H. L., et al. 2014. Biochem. J. 459, 427. |
Product Information | |
---|---|
Form | Orange red powder |
Hill Formula | C₁₃H₉ClN₄O₃ |
Chemical formula | C₁₃H₉ClN₄O₃ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | p38 MAPK |
Primary Target IC<sub>50</sub> | 6.31 µM for p38 MAPK-mediated phosphorylation of MEF-2A-Thr312 |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
530486 | 0 |
Documentation
p38 MAP Kinase Inhibitor XX, FGA-19 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Willemen, H. L., et al. 2014. Biochem. J. 459, 427. |
Data Sheet | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
|